KLRA vs NUVB: stock comparison and AI forecast
Kailera Therapeutics, Inc. (KLRA) and Nuvation Bio Inc. (NUVB) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KLRA Kailera Therapeutics, Inc.
- Market Cap
- $1.58B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
NUVB Nuvation Bio Inc.
- Market Cap
- $1.47B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- KLRA and NUVB have similar market capitalizations ($1.58B and $1.47B).
- NUVB carries 2.41 times debt per unit of equity, against 0.05 times for KLRA.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KLRA | NUVB |
|---|---|---|
| Market Cap | $1.58B | $1.47B |
| P/B Ratio | 1.53x | 6.45x |
| EPS | – | $-0.56 |
| Book Value/Share | $7.95 | $0.65 |
| Revenue/Share | – | $0.57 |
Profitability & Margins
| Metric | KLRA | NUVB |
|---|---|---|
| ROE | – | -59.6% |
| ROA | – | -17.5% |
| ROIC | – | -18.1% |
| Gross Margin | – | 93.9% |
| Operating Margin | – | -61.2% |
| Net Margin | – | -67.4% |
| EBT Margin | – | -67.4% |
| Tax Rate | – | 0.0% |
Financial Health
| Metric | KLRA | NUVB |
|---|---|---|
| Current Ratio | 21.84x | 7.45x |
| Quick Ratio | – | 7.30x |
| D/E Ratio | 0.05x | 2.41x |
| Financial Leverage | 1.05x | 3.41x |
| Interest Coverage | – | -47.9x |
| Working Capital | $878M | $636M |
Cash Flow
| Metric | KLRA | NUVB |
|---|---|---|
| Operating Cash Flow | – | -$106M |
Operational Efficiency
| Metric | KLRA | NUVB |
|---|---|---|
| Asset Turnover | – | 0.26x |
| Receivables Turnover | – | 5.5x |
| Inventory Turnover | – | 0.8x |
| Fixed Assets Turnover | – | 90.9x |
| Days Sales Outstanding | – | 66 days |
| Days Inventory | – | 458 days |
| Payables Period | – | 282 days |
| Cash Conversion Cycle | – | 242 days |
Income Statement
| Metric | KLRA | NUVB |
|---|---|---|
| Total Revenue | – | $202M |
| Operating Income | – | -$123M |
| Net Income | – | -$136M |
| R&D Expense | – | $133M |
| SG&A Expense | – | $164M |
| Cost of Goods Sold | – | $12M |
Dividend & Shareholder Information
| Metric | KLRA | NUVB |
|---|---|---|
| Shares Outstanding | 130M | 351M |
KLRA vs NUVB: stock comparison and AI forecast
Which is bigger, KLRA or NUVB?
KLRA and NUVB have similar market capitalizations ($1.58B and $1.47B).
Which one does Intratio's AI model rank higher, KLRA or NUVB?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.